MARKET

ZNTL

ZNTL

Zentalis Pharmaceuticals, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

78.19
+4.78
+6.51%
After Hours: 78.19 0 0.00% 16:13 12/02 EST
OPEN
72.16
PREV CLOSE
73.41
HIGH
79.34
LOW
72.16
VOLUME
318.79K
TURNOVER
--
52 WEEK HIGH
87.19
52 WEEK LOW
34.48
MARKET CAP
3.54B
P/E (TTM)
-21.2646
1D
5D
1M
3M
1Y
5Y
Zentalis Pharmaceuticals to Host Virtual Research and Development (R&D) Day on December 16, 2021
Webcast to be held on Thursday, December 16 at 11:00 a.m. EST...
Globe Newswire · 18h ago
Zentalis Pharmaceuticals Inc (ZNTL) COO Kevin D. Bunker Sold $759,900 of Shares
GuruFocus News · 11/24 13:15
Zentalis Pharmaceuticals Insider Sold Over $750K In Company Stock
Cam Gallagher, Insider at Zentalis Pharmaceuticals (NASDAQ:ZNTL), made a large insider sell on November 15, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Gallagher sold ...
Benzinga · 11/17 16:35
BRIEF-Zentalis Pharmaceuticals Announces U.S. FDA Fast Track Designation Uterine Serous Carcinoma Treatment
reuters.com · 11/17 12:19
FDA grants Fast Track tag for Zentalis Pharma's ZN-c3 in uterine serous carcinoma
Zentalis Pharmaceuticals (NASDAQ:ZNTL) announces that the FDA has granted Fast Track designation to ZN-c3, an oral WEE1 inhibitor product candidate, for the treatment of recurrent or persistent uterine serous carcinoma
Seekingalpha · 11/17 12:18
Zentalis Pharmaceuticals Announces Fast Track Designation Granted by the U.S. FDA to ZN-c3 for the Treatment of Uterine Serous Carcinoma
Potentially registrational Phase 2 trial of ZN-c3 in USC is underway, with initial enrollment and safety update expected in 2H 2022NEW YORK and SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage bio...
GlobeNewswire · 11/17 12:00
HC Wainwright & Co. Maintains Buy on Zentalis Pharmaceuticals, Raises Price Target to $120
HC Wainwright & Co. analyst Andrew Fein maintains Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Buy and raises the price target from $80 to $120.
Benzinga · 11/11 11:17
--HC Wainwright Adjusts Price Target on Zentalis Pharmaceuticals to $120 From $80, Reiterates Buy Rating
MT Newswires · 11/11 06:55
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZNTL. Analyze the recent business situations of Zentalis Pharmaceuticals, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

66.67%Strong Buy
33.33%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ZNTL stock price target is 97.67 with a high estimate of 120.00 and a low estimate of 84.00.
High120.00
Average97.67
Low84.00
Current 78.19
EPS
Actual
Estimate
-1.07-0.80-0.54-0.27
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 122
Institutional Holdings: 42.08M
% Owned: 92.89%
Shares Outstanding: 45.31M
TypeInstitutionsShares
Increased
59
2.96M
New
15
290.47K
Decreased
27
772.83K
Sold Out
18
947.67K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.06%
Key Executives
Chairman/President/Chief Executive Officer/Executive Director
Anthony Sun
Co-Founder/Chief Operating Officer
Kevin Bunker
Chief Financial Officer/Treasurer
Melissa Epperly
Senior Vice President
Dimitris Voliotis
Secretary
Alexis Pinto
Lead Director/Independent Director
David Johnson
Director
Cam Gallagher
Independent Director
Kimberly Blackwell
Independent Director
Enoch Kariuki
Independent Director
Karan Takhar
No Data
  • All
  • Financials
  • Insiders
More
About ZNTL
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidates, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors. Its other products include ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of non-Hodgkin’s lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.

Webull offers kinds of Zentalis Pharmaceuticals Inc stock information, including NASDAQ:ZNTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZNTL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZNTL stock methods without spending real money on the virtual paper trading platform.